• Latest Posts

Adaptimmune’s TCR Therapy Proves its Superiority over its Immuno-oncology Competitors

Theravectys’ HIV Cure on the Road to Success

How Servier saved Cellectis, the French CAR-T Miracle

Video: Discover How CAR-T Therapies are Working

Celyad, the new face of Cardio3, is launching an IPO on NASDAQ

[Update] AstraZeneca to buy a CAR-T expert?

ADVERTISEMENT

Pfizer to Control Cellectis in a €1.5 Billion Deal?

[UPDATE] Adaptimmune raised €156.7M in its IPO

US-based Juno Therapeutics purchased a German biotech

Cardio3, the leading Stem Cell Biotech gets a US patent on CAR-T

Gene editing to make French fries less unhealthy

Merck Serono and Intrexon, to develop CAR-T Therapy

ADVERTISEMENT